A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects
An Open-Label, Single Center, Nonrandomized, Phase 1 Study to Evaluate Safety and Efficacy of Using the Combination Treatment of SHR-1210, Gemcitabine and Cis-platinum by Recurrent and Metastatic NPC
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This PHASE1 trial investigates Nasopharyngeal Carcinoma and is currently completed. Jiangsu HengRui Medicine Co., Ltd. leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Jan 2021 — Sep 2022 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jan 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE1
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Jul 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .